These observations support the continued development of selective metabolic inhibitors for the treatment of ALL, particularly for patients that are likely to be GC resistant, such as those with MLL rearrangements, induction failure or relapse. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.